

Historical Information

Provided by: Senhwa Biosciences, Inc.

SEQ_NO 1 Date of announcement 2024/03/20 Time of announcement 15:11:14

Subject Senhwa announces the first patient dosed in the phase II study of CX-4945 with Community-Acquired Pneumonia associated with viral infection in Taiwan.

Date of events 2024/03/20 To which item it meets paragraph 53

Statement

1.Date of occurrence of the event:2024/03/20
2.Company name:Senhwa Biosciences Inc.
3.Relationship to the Company (please enter "head office" or "subsidiaries"):Headquarter
4.Reciprocal shareholding ratios:Not applicable
5.Cause of occurrence:
(1)The Company's phase II study of Silmitasertib in patients with Community-Acquired Pneumonia (CAP) associated with viral infection, today has successfully recruited the first patient at the National Taiwan University Hospital.
(2)This trial is planned to be executed at the five sites including National Taiwan University Hospital, National Taiwan University Cancer Center, Far Eastern Memorial Hospital, Tri-Service General Hospital and Taoyuan General Hospital Ministry of Health and Welfare.
(3)SARS-CoV-2 and Influenza viruses have the characteristics of constant mutation and may cause epidemics after evolution. The World Health Organization has issued a latest warning at the World Government Summit, stating that the next wave of Disease X following the COVID-19 pandemic may erupt, possibly caused by influenza viruses, novel coronaviruses, or a new pathogen unknown to humans. Silmitasertib (CX-4945) developed by Senhwa Biosciences possesses a novel mechanism that targets human host cells, making it less susceptible to the effects of viral mutations. The purpose of this trial is to give early medical intervention in the course of the disease with Silmitasertib (CX-4945) to prevent the progression of CAP, to avoid hospitalization and enhance the subject's clinical condition, while reducing the risks associated with elevated cytokine release related to infections of new coronaviruses or influenza viruses. Please refer to the company's important information released on October 19, 2023 for details of this trial plan.
(4)A single clinical trial result does not reflect the success or failure of new drug development and launch in the future. Investors should make prudent judgments and investments.
6.Countermeasures:Upload the important information on Market Observation Post System.
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None. Drug development requires huge amount of time and investment, and there is no guarantee of success, which may put the investment at risk. Investors should make prudent judgments on investments.